Table 1. CD209 -336A/G SNP in Patients Enrolled in Tuberculosis Case Control Studies in Four Countries.
Variant | The Gambia | Republic of Guinea | Guinea-Bissau | Malawi | |||||
Cases (A) | Cases (B) | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
n = 329 | n = 347 | n = 327 | n = 151 | n = 180 | n = 162 | n = 141 | n = 244 | n = 295 | |
AA | 26.7 | 28.0 | 22.0 | 28.3 | 29.8 | 32.7 | 25.5 | 43.5 | 38.3 |
AG | 52.6 | 48.1 | 48.0 | 45.6 | 46.4 | 39.5 | 48.2 | 42.6 | 50.5 |
GG | 20.7 | 23.9 | 30.0 | 26.1 | 23.8 | 27.8 | 26.3 | 13.9 | 11.2 |
χ2 | 7.79 | 4.66 | – | 0.24 | – | 2.71 | – | 3.45 | – |
P value | 0.020 | 0.097 | – | 0.886 | – | 0.258 | – | 0.178 | – |
Genotypic frequency and genotypic association (3×2 χ2, 2 degrees of freedom) for CD209 -336A/G (rs4804803) from 2176 individuals enrolled in tuberculosis case control studies from The Gambia (A), Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B) (ref. 34) and Malawi (ref. 35). Significance level of P<0.05 is indicated in bold.